Atopaxar 751475-53-3 Atopaxar is a reversible protease activated receptor (PAR)-1 thrombin receptor antagonist that interferes with platelet signaling.

Cinaciguat 329773-35-5 Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.

HA14-1 65673-63-4 HA14-1 is a non-peptidic ligand of a Bcl-2 surface pocket with IC50 of ~9 μM.

AVN944 297730-17-7 AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.

YL-109 36341-25-0 YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

L-779450 303727-31-3 L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays 7, 30 and 70-fold selectivity over p38α, GSK3β and Lck respectively.

Asenapine Maleate 85650-56-2 Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered

FLT3-IN-2 923562-23-6 FLT3-IN-2 is a FLT3 inhibitor with IC50 of ＜ 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.